Pharmacology and clinical potential of vortioxetine in the treatment of major depressive disorder

References

• AlonsoJAngermeyerMCBernertSESEMeD/MHEDEA 2000 InvestigatorsEuropean Study of the Epidemiology of Mental Disorders (ESEMeD) ProjectPrevalence of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) projectActa Psychiatr Scand Suppl2004420212715128384
   PubMedGoogle Scholar
• GuzeSBRobinsESuicide and primary affective disordersBr J Psychiatry19701175394374385481206
   PubMed Web of Science ®Google Scholar
• de Diego-AdeliñoJPiresPGómez-AnsónBMicrostructural white-matter abnormalities associated with treatment resistance, severity and duration of illness in major depressionPsychol Med Epub2013821
   Web of Science ®Google Scholar
• Serra-BlascoMPortellaMJGómez-AnsónBEffects of illness duration and treatment resistance on grey matter abnormalities in major depressionBr J Psychiatry201320243444023620451
   PubMed Web of Science ®Google Scholar
• ValladaresADillaTSacristánJADepression: a social mortgage. Latest advances in knowledge of the cost of the diseaseActas Esp Psiquiatr20093714953 Spanish18781410
   PubMed Web of Science ®Google Scholar
• MathersCDLoncarDProjections of global mortality and burden of disease from 2002 to 2030PLoS Med2006311e44217132052
   PubMed Web of Science ®Google Scholar
• Bang-AndersenBRuhlandTJørgensenMDiscovery of 1-[2-(2,4-dimethylphenylsulfanyl) phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorderJ Med Chem20115493206322121486038
   PubMed Web of Science ®Google Scholar
• MørkAPehrsonABrennumLTPharmacological effects of Lu AA21004: a novel multimodal compound for the treatment of major depressive disorderJ Pharmacol Exp Ther2012340366667522171087
   PubMed Web of Science ®Google Scholar
• ArebergJLuntang-JensenMSøgaardBNilausenDØOccupancy of the serotonin transporter after administration of Lu AA21004 and its relation to plasma concentration in healthy subjectsBasic Clin Pharmacol Toxicol2012110440140421985522
   PubMed Web of Science ®Google Scholar
• PehrsonALCremersTBétryCLu AA21004, a novel multimodal antidepressant, produces regionally selective increases of multiple neurotransmitters – a rat microdialysis and electrophysiology studyEur Neuropsychopharmacol201323213314522612991
   PubMed Web of Science ®Google Scholar
• ArtigasFSerotonin receptors involved in antidepressant effectsPharmacol Ther2013137111913123022360
   PubMed Web of Science ®Google Scholar
• ArtigasFPerezVAlvarezEPindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitorsArch Gen Psychiatry19945132482518122960
   PubMed Web of Science ®Google Scholar
• ArtigasFRomeroLde MontignyCBlierPAcceleration of the effect of selected antidepressant drugs in major depression by 5-HT1A antagonistsTrends Neurosci19961993783838873352
   PubMed Web of Science ®Google Scholar
• RigaMSCeladaPSanchezCArtigasFRole of 5-HT3 receptors in the mechanism of action of the investigational antidepressant vortioxetineEur Neuropsychopharm2013Suppl 2S393S394
   Web of Science ®Google Scholar
• HvenegaardMGBang-AndersenBPedersenHJørgensenMPüschlADalgaardLIdentification of the cytochrome P450 and other enzymes involved in the in vitro oxidative metabolism of a novel antidepressant, Lu AA21004Drug Metab Dispos20124071357136522496396
   PubMed Web of Science ®Google Scholar
• JainRMahableshwarkarARJacobsenPLChenYThaseMEA randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorderInt J Neuropsychopharmacol201316231332122963932
   PubMed Web of Science ®Google Scholar
• BaldwinDSLoftHDragheimMA randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD)Eur Neuropsychopharmacol201222748249122209361
   PubMed Web of Science ®Google Scholar
• MahableshwarkarARJacobsenPLSerenkoMChenYTrivediMHA duloxetine-referenced, fixed dose study comparing efficacy and safety of 2 vortioxetine doses in the acute treatment of adult MDD patientsPoster Presented at: American Psychiatry Association Annual MeetingMay 18–22, 2013San Francisco, CA
   Google Scholar
• McIntyreRSLophavenSOlsenCKRandomized, double-blind, placebo-controlled study of the efficacy of vortioxetineon cognitive function in adult patients with major depressive disorder (MDD)Poster presented at: 52nd Annual Meeting of the American College of Neuropsychopharmacology (ACNP)December 8–12, 2013Hollywood, FL
   Google Scholar
• HäggströmLNielsenRZPoulsenLDanchenkoNA randomised, double blind, active controlled study of vortioxetine (10–20 mg/day) versus agomelatine 25–50 mg/day) in adults with Major Depressive Disorder with inadequate response to antidepressant treatmentPoster presented at: 26th Congress of the European College of Neuropsychopharmacology (ECNP)October 5–9, 2013Barcelona, Spain
   Google Scholar
• JacobsenPLMahableshwarkarARSerenkoMChanSTrivediMHA randomized, double-blind, placebo-controlled study of the efficacy and safety of vortioxetine 10 mg and 20 mg in adults with Major Depressive DisorderPoster presented at: American Psychiatry Association Annual MeetingMay 18–22, 2013San Francisco, CA
   Google Scholar
• MahableshwarkarARJacobsenPLChenYA randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorderCurr Med Res Opin201329321722623252878
   PubMed Web of Science ®Google Scholar
• MahableshwarkarARJacobsenPLSerenkoMChenYTrivediMHA randomized, double blind, parallel, placebo-controlled, fixed-dose study comparing the efficacy and safety of 2 doses of vortioxetine (LU AA21004) in acute treatment of adults with major depressive disorderPoster presented at: American Psychiatry Association Annual MeetingMay 18–22, 2013San Francisco, CA
   Google Scholar
• AlvarezEPerezVDragheimMLoftHArtigasFA double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorderInt J Neuropsychopharmacol201215558960021767441
   PubMed Web of Science ®Google Scholar
• HenigsbergNMahableshwarkarARJacobsenPChenYThaseMEA randomized, double-blind, placebo-controlled 8-week trial of the efficacy and tolerability of multiple doses of Lu AA21004 in adults with major depressive disorderJ Clin Psychiatry201273795395922901346
   PubMed Web of Science ®Google Scholar
• KatonaCHansenTOlsenCKA randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorderInt Clin Psychopharmacol201227421522322572889
   PubMed Web of Science ®Google Scholar
• BoulengerJPLoftHOlsenCKEfficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: a randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorderInt Clin Psychopharmacol201429313814924257717
   PubMed Web of Science ®Google Scholar
• BoulengerJPLoftHFloreaIA randomized clinical study of Lu AA21004 in the prevention of relapse in patients with major depressive disorderJ Psychopharmacol201226111408141622495621
   PubMed Web of Science ®Google Scholar
• BaldwinDSHansenTFloreaIVortioxetine (Lu AA21004) in the long-term open-label treatment of major depressive disorderCurr Med Res Opin201228101717172422978748
   PubMed Web of Science ®Google Scholar
• MillanMJGobertALejeuneFThe novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathwaysJ Pharmacol Exp Ther2003306395496412750432
   PubMed Web of Science ®Google Scholar
• SerrettiAChiesaATreatment-emergent sexual dysfunction related to antidepressants: a meta-analysisJ Clin Psychopharmacol200929325926619440080
   PubMed Web of Science ®Google Scholar
• NicolosiALaumannEOGlasserDBMoreiraEDJrPaikAGingellCGlobal Study of Sexual Attitudes and Behaviors Investigators’ GroupSexual behavior and sexual dysfunctions after age 40: the global study of sexual attitudes and behaviorsUrology200464599199715533492
   PubMed Web of Science ®Google Scholar
• AmstislavskayaTGPopovaNKThe roles of different types of serotonin receptors in activation of the hypophyseal-testicular complex induced in mice by the presence of a femaleNeurosci Behav Physiol200434883383715587814
   PubMedGoogle Scholar
• KhinNAChenYFYangYYangPLaughrenTPExploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applicationsJ Clin Psychiatry201172446447221527123
   PubMed Web of Science ®Google Scholar
• MundtJCGreistJHJeffersonJWIs it easier to find what you are looking for if you think you know what it looks like?J Clin Psychopharmacol200727212112517414233
   PubMed Web of Science ®Google Scholar
• Stewart-WilliamsSPoddJThe placebo effect: dissolving the expectancy versus conditioning debatePsychol Bull2004130232434014979775
   PubMed Web of Science ®Google Scholar
• CitromeLVortioxetine for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant – what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?Int J Clin Pract2014681608224165478
   PubMed Web of Science ®Google Scholar